Keyword search (3,448 papers available)


Pre-treatment EEG signal variability is associated with treatment success in depression.

Author(s): Jaworska N, Wang H, Smith DM, Blier P, Knott V, Protzner AB

Neuroimage Clin. 2018;17:368-377 Authors: Jaworska N, Wang H, Smith DM, Blier P, Knott V, Protzner AB

Article GUID: 29159049
Effect of GAD1 genotype status on auditory attention and acute nicotine administration in healthy volunteers.

Author(s): Hadjis E, Hyde M, Choueiry J, Jaworska N, Nelson R, de la Salle S, Smith D, Aidelbaum R, Knott V

Hum Psychopharmacol. 2019 Jan;34(1):e2684 Authors: Hadjis E, Hyde M, Choueiry J, Jaworska N, Nelson R, de la Salle S, Smith D, Aidelbaum R, Knott V

Article GUID: 30488987
Title:Effect of GAD1 genotype status on auditory attention and acute nicotine administration in healthy volunteers.
Authors:Hadjis E,  Hyde M,  Choueiry J,  Jaworska N,  Nelson R,  de la Salle S,  Smith D,  Aidelbaum R,  Knott V
Link:https://www.ncbi.nlm.nih.gov/pubmed/30488987?dopt=Abstract
Category:Hum Psychopharmacol
PMID:30488987
Dept Affiliation: CSBN
1 Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
2 University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada.
3 Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
4 School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.
5 Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Quebec, Canada.

Description:

Effect of GAD1 genotype status on auditory attention and acute nicotine administration in healthy volunteers.

Hum Psychopharmacol. 2019 Jan;34(1):e2684

Authors: Hadjis E, Hyde M, Choueiry J, Jaworska N, Nelson R, de la Salle S, Smith D, Aidelbaum R, Knott V

Abstract

OBJECTIVE: The effects of GABA modulating drugs and nicotine, the prototypical nicotinic cholinergic agonist, on attention have been investigated using subcomponents of the P300 event-related potentials (ERP), which index involuntary (P3a) and voluntary attention (P3b). However, investigations into how such pharmacologic effects interact with genetic features in the GABA system remain unclear. This study examined the moderating effects of a single nucleotide polymorphism (rs7557793) in the glutamic acid decarboxylase 67 (GAD1) gene, which is implicated in the conversion of glutamate to GABA, on P300-indices of auditory attentional processing; the influence of nicotine administration was also assessed.

METHODS: The effects of GAD1 genotype (TT/CC/CT) were examined on the P3a/b in response to an auditory selective attention task in healthy, nonsmoking male volunteers (N = 126; 18-40 years). Participants responded to rare target stimuli (P3b-eliciting) and ignored frequent nontarget stimuli as well as rare distractor stimuli (P3a-eliciting). In a subsample (N = 59), P3a/b profiles to acute nicotine (vs. placebo) administration were examined as a function of GAD1 genotype. As a secondary aim, earlier sensory processes were assessed with N200 ERP subcomponents elicited by novel (N2a) and target (N2b) auditory stimuli.

RESULTS: GAD1 allelic variation moderated early sensory processes, enhancing N2a amplitudes in CT versus TT carriers. Further, TT homozygotes exhibited larger P3b amplitudes than CC homozygotes in the placebo versus nicotine condition. Regardless of genotype, nicotine versus placebo moderated the N200 ERP.

CONCLUSION: These findings expand our knowledge regarding the attentional effects of GAD1 genetic variants in relation to nicotine.

PMID: 30488987 [PubMed - in process]